Moreover, TBC1D10B was a significant risk factor for overall survival in several LIHC clinicopathological subgroups, including age above 60 years (HR = 1.65; P = 0.033), clinical stages I − II (HR = 1.64; P = 0.045), clinical stages T1 and T2 (HR = 1.72; P = 0.021), clinical N0 stage (HR = 1.80; P = 0.009), clinical M0 stage (HR = 1.58; P = 0.038), non-overweight (HR = 1.71; P = 0.04), no residual tumor (HR = 1.57; P = 0.02), prothrombin time less than 4 s (HR = 1.81; P = 0.033), and liver fibrosis (HR = 2.22; P = 0.03) (Table 3 and Fig. 6). This evidence concerns the gene F2 and neoplasm.